Immedica Pharma US, INC.

Reporting payments is a legal requirement; large totals often reflect large product portfolios.

$1.0Mgeneral payments (2019-2025)
$23Kresearch payments (2019-2025)
1,234clinicians paid

General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.

General payments by year

2022 $111K
2023 $590K
2024 $279K
2025 $66K

General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.

Products most associated with its payments

Specialties it works with most

Internal Medicine $369K
Neurology With Special Qualifications In Child Neurology $338K
Neurology (Psychiatry & Neurology) $191K
Pediatrics $19K
Clinical Neurophysiology $12K
Pediatric Endocrinology $10K

Clinicians with the largest reported totals

Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.

ClinicianLocationSpecialtyGeneral payments (2019-2025)
Sarah Noonberg Castro Valley, CA Internal Medicine $368,578.43
Michael Rogawski Sacramento, CA Neurology (Psychiatry & Neurology) $70,889.66
Rajsekar Rajaraman Los Angeles, CA Neurology With Special Qualifications In Child Neurology $48,776.02
Jesus Pina Garza Nashville, TN Neurology With Special Qualifications In Child Neurology $42,421.32
Alison Dolce Irving, TX Neurology With Special Qualifications In Child Neurology $20,701.87
Michael Perry Fort Worth, TX Neurology With Special Qualifications In Child Neurology $20,596.68
Mary Kay Koenig Houston, TX Neurology With Special Qualifications In Child Neurology $20,190.01
Steven Wolf New York, NY Neurology (Psychiatry & Neurology) $20,055.49
Santiago Arroyo Charlestown, MA Neurology (Psychiatry & Neurology) $19,386.27
James Wheless Memphis, TN Neurology With Special Qualifications In Child Neurology $18,571.04

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.